Recent Quotes
My Watchlist
Indicators
REW 40 Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Niagen Bioscience, Inc. - Common Stock (NQ:NAGE)

3.530 +0.130 (+3.82%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,263,815
Open 3.500
Bid (Size) 3.440 (100)
Ask (Size) 3.500 (2,000)
Prev. Close 3.400
Today's Range 3.430 - 3.580
52wk Range 3.115 - 11.29
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biological Aging
From Niagen Bioscience, Inc
Via Business Wire

Performance

YTD
-43.5%
-43.5%
1 Month
+0.9%
+0.9%
3 Month
-28.4%
-28.4%
6 Month
-42.0%
-42.0%
1 Year
-63.4%
-63.4%

More News

Read More
Niagen Bioscience (NASDAQ:NAGE) Shares Slide After Q1 Earnings Miss and Spending Guidance ↗
Via Chartmill
Topics Earnings
Niagen Bioscience Inc (NASDAQ:NAGE) Reports Q4 2025 Revenue Beat and Mixed Earnings ↗
Via Chartmill
News headline image
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
From Niagen Bioscience, Inc.
Via Business Wire
News headline image
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen (NAGE) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
From Niagen Bioscience, Inc
Via Business Wire
Four Stocks at the Intersection of Enzymes, Longevity, and the $400 Billion Wellness Boom (CELV, NAGE, MTEX, CDXS)
Via AB Newswire
News headline image
Niagen Bioscience Increases Share Repurchase Program to $20 Million
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience to Present at the 38th Annual ROTH Conference
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
From Niagen Bioscience, Inc
Via Business Wire
News headline image
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
From Niagen Bioscience, Inc
Via Business Wire

Frequently Asked Questions

Is Niagen Bioscience, Inc. - Common Stock publicly traded?
Yes, Niagen Bioscience, Inc. - Common Stock is publicly traded.
What exchange does Niagen Bioscience, Inc. - Common Stock trade on?
Niagen Bioscience, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Niagen Bioscience, Inc. - Common Stock?
The ticker symbol for Niagen Bioscience, Inc. - Common Stock is NAGE on the Nasdaq Stock Market
What is the current price of Niagen Bioscience, Inc. - Common Stock?
The current price of Niagen Bioscience, Inc. - Common Stock is 3.530
When was Niagen Bioscience, Inc. - Common Stock last traded?
The last trade of Niagen Bioscience, Inc. - Common Stock was at 08/03/26 04:00 PM ET
What is the market capitalization of Niagen Bioscience, Inc. - Common Stock?
The market capitalization of Niagen Bioscience, Inc. - Common Stock is 240.73M
How many shares of Niagen Bioscience, Inc. - Common Stock are outstanding?
Niagen Bioscience, Inc. - Common Stock has 241M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.